SIMT Stereotactic Radiosurgery Outcomes Study (SIMT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02886572 |
Recruitment Status :
Active, not recruiting
First Posted : September 1, 2016
Last Update Posted : August 5, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain Metastases, Adult | Radiation: Stereotactic radiosurgery | Not Applicable |
Forty patients with four or more brain metastases will be enrolled prior to radiosurgery. A planning MRI brain scan will be performed with GD-DPTA within one week prior to radiosurgery, per the standard of care. Neurocognitive (Mini-Mental Status Examination (MMSE), Trail-making test A&B, Hopkins Learning Verbal (HVLT)) and functional assessment of cancer therapy-brain (FACT- Br) will be obtained prior to radiosurgery. Dose will be prescribed to the maximum isodose line encompassing the resulting PTV using the dose guidelines as described below.
The primary endpoint will be the proportion of patients who live longer than predicted based on the diagnosis-specific GPA score. The Kaplan-Meier estimator will be used to describe the survival of all patients treated with SIMT SRS. Secondary endpoints will be the rate of recurrence at the treated metastases sites, the rate of new brain metastases at a site different from the SRS-treated metastases sites, the rate of death due to neurological causes, and the prevalence of significant adverse events. Exploratory endpoints include change over time in neurocognition and quality of life, quantification of dosimetric measures, the rate of salvage therapy, the rate of radionecrosis at the SRS treatment sites, and the rate and intensity of steroid-usage post-SRS.
All patients will be evaluated for neurocognitive function via MMSE, HVLT, and Trail-making tests A & B, quality of life via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study. These evaluations will be done at regular follow-up evaluations or when local recurrence is suspected on the basis of symptoms. Distant recurrence is defined as the appearance of new brain metastases at a site different from that of the original metastases. Recurrence will further be defined as a new area of enhancement that measures greater than 5 millimeters in the axial plane on MRI. The length of time to recurrence of the original brain metastases will be calculated from the date of the brain metastases radiosurgery to the date that a recurrence was detected by MRI. Patients with suspected recurrent tumor and/or who are symptomatic may undergo a stereotactic biopsy to evaluate for radionecrosis versus recurrent brain metastases, as is standard of care.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Outcome in Patients With 4 or More Brain Metastases Treated With Single-Isocenter, Multi-Target (SIMT) Stereotactic Radiosurgery: A Prospective Single-arm Study in Adults With Brain Metastases |
Actual Study Start Date : | May 12, 2017 |
Estimated Primary Completion Date : | August 23, 2021 |
Estimated Study Completion Date : | August 23, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Stereotactic Radiosurgery
All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
|
Radiation: Stereotactic radiosurgery
Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
Other Name: SRS |
- Proportion of patients who live longer than predicted according to the Graded Prognostic Assessment (GPA) score [ Time Frame: Up to 24 months after SRS ]
- Proportion of patients that experience local brain recurrence within 1 year of SIMT SRS treatment. [ Time Frame: Up to 12 months after SRS ]Serial MRI's
- Proportion of patients who are dead within 1 year of SIMT SRS treatment due to neurologic reasons [ Time Frame: Up to 12 months after SRS ]
- Proportion of patients that experience a new brain metastasis at a site different from the original brain metastasis site 1 year after SIMT SRS treatment [ Time Frame: Up to 12 months after SRS ]Serial MRI's
- Proportion of patients who experience grade 3, 4, or 5 neurologic adverse events attributable to SIMT SRS [ Time Frame: Up to 12 months after SRS ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- A contrast-enhanced MRI scan showing = or > 4 brain metastases.
- Age >/=18 years of age.
- KPS >/= 70
- Patient must have a graded prosnostic score (GPA) score 0.5 or greater
- Life expectancy of at least 3 months
- Postoperative patients with resected brain metastases are eligible.
- Largest lesion < 4cm diameter
- Must be a candidate for MRI imaging
- Previous cranial stereotactic radiosurgery (SRS) or whole brain radiation therapy (WBRT) is allowed if > 3 months prior to SIMT
- Must be capable of providing informed consent
Exclusion Criteria:
- Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myeloma).
- Metastases within 2 mm of the optic apparatus
- Patients unable to obtain MRI
- Evidence of leptomeningeal disease
- Greater than 10 brain metastases
- Pregnant women are excluded

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02886572
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 |
Principal Investigator: | Grace J. Kim, MD PhD | Duke University Medical Center, Radiation Onoclogy |
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT02886572 |
Other Study ID Numbers: |
Pro00075429 |
First Posted: | September 1, 2016 Key Record Dates |
Last Update Posted: | August 5, 2020 |
Last Verified: | August 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Neoplasm Metastasis Neoplastic Processes Neoplasms Pathologic Processes |